These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38245505)

  • 21. Time-Restricted Feeding Attenuates Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma in Obese Male Mice.
    Das M; Kumar D; Sauceda C; Oberg A; Ellies LG; Zeng L; Jih LJ; Newton IG; Webster NJG
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Liu H; Yerevanian A; Westerhoff M; Hastings MH; Guerra JRB; Zhao M; Svensson KJ; Cai B; Soukas AA; Rosenzweig A
    Diabetes; 2024 Feb; 73(2):260-279. PubMed ID: 37934943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review.
    Castagneto-Gissey L; Bornstein SR; Mingrone G
    Metabolism; 2024 Feb; 151():155721. PubMed ID: 37923007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Sep; 264(1):101-111. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression.
    Piras IS; DiStefano JK
    Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38565287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of tyrosine derivatives as peripheral 5HT
    Kim M; Choi W; Yoon J; Jeong BK; Pagire SH; Pagire HS; Park J; Nam JE; Oh CJ; Jeon JH; Kim SS; Lee BH; Song JS; Bae MA; Lee IK; Kim H; Ahn JH
    Eur J Med Chem; 2022 Sep; 239():114517. PubMed ID: 35732081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A natural language processing algorithm accurately classifies steatotic liver disease pathology to estimate the risk of cirrhosis.
    Sherman MS; Challa PK; Przybyszewski EM; Wilechansky RM; Uche-Anya EN; Ott AT; McGoldrick J; Goessling W; Khalili H; Simon TG
    Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38551386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis.
    Lyu J; Okada H; Sunagozaka H; Kawaguchi K; Shimakami T; Nio K; Murai K; Shirasaki T; Yoshida M; Arai K; Yamashita T; Tanaka T; Harada K; Takamura T; Kaneko S; Yamashita T; Honda M
    Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38619434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imbalance of mitochondrial fusion in peripheral blood mononuclear cells is associated with liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis.
    Kunlayawutipong T; Apaijai N; Tepmalai K; Kongkarnka S; Leerapun A; Pinyopornpanish K; Soontornpun A; Chattipakorn SC; Chattipakorn N; Pinyopornpanish K
    Heliyon; 2024 Mar; 10(6):e27557. PubMed ID: 38496899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
    Ni K; Meng L
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102381. PubMed ID: 38821484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction-associated steatohepatitis.
    Steffani M; Geng Y; Pajvani UB; Schwabe RF
    J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma.
    Wang H; Tsung A; Mishra L; Huang H
    EBioMedicine; 2024 Mar; 101():105031. PubMed ID: 38401419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
    Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
    Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel insights into metabolic-associated steatotic liver disease preclinical models.
    Montero-Vallejo R; Maya-Miles D; Ampuero J; Martín F; Romero-Gómez M; Gallego-Durán R
    Liver Int; 2024 Mar; 44(3):644-662. PubMed ID: 38291855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.
    Kokkorakis M; Muzurović E; Volčanšek Š; Chakhtoura M; Hill MA; Mikhailidis DP; Mantzoros CS
    Pharmacol Rev; 2024 May; 76(3):454-499. PubMed ID: 38697855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitis.
    Qin X; Liu J
    Acta Biomater; 2024 Aug; 184():37-53. PubMed ID: 38879104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
    Matsumoto M; Hada N; Sakamaki Y; Uno A; Shiga T; Tanaka C; Ito T; Katsume A; Sudoh M
    Int J Exp Pathol; 2013 Apr; 94(2):93-103. PubMed ID: 23305254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Syed-Abdul MM
    Metabolites; 2023 Dec; 14(1):. PubMed ID: 38248815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.